Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.57 |
| ▸ | BRD4 | O60885 | 3/20 | 0.56 |
| ▸ | MAP1LC3B | Q9GZQ8 | 5/20 | 0.54 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.53 |
| ▸ | TNF | P01375 | 1/20 | 0.53 |
| ▸ | IL1B | P01584 | 1/20 | 0.53 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.53 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.53 |
| ▸ | STAT3 | P40763 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21855255 | 1.00 | CRBN (0.57) | CRBNBRD4MAP1LC3BIKZF3TNF | |
| SCHEMBL30628170 | 0.92 | CRBN (0.62) | CRBNBRD4MAP1LC3BIKZF3TNF | |
| SCHEMBL16569451 | 0.92 | CRBN (0.62) | CRBNBRD4MAP1LC3BIKZF3TNF | |
| SCHEMBL30577345 | 0.91 | CRBN (0.55) | CRBNBRD4MAP1LC3BIKZF3TNF | |
| SCHEMBL22252682 | 0.91 | CRBN (0.55) | CRBNBRD4MAP1LC3BIKZF3TNF | |
| SCHEMBL19438857 | 0.91 | CRBN (0.55) | CRBNBRD4MAP1LC3BIKZF3TNF | |
| SCHEMBL20913661 | 0.91 | CRBN (0.55) | CRBNBRD4MAP1LC3BIKZF3TNF | |
| SCHEMBL19438825 | 0.91 | CRBN (0.55) | CRBNBRD4MAP1LC3BIKZF3TNF | |
| SCHEMBL22464461 | 0.90 | CRBN (0.60) | CRBNBRD4MAP1LC3BIKZF3TNF | |
| SCHEMBL464519 | 0.90 | CRBN (0.60) | CRBNBRD4MAP1LC3BIKZF3TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| CN-118955473-A | Difunctional compounds for degrading BTK via the ubiquitin proteasome pathway | 紐力克斯治疗公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-113412259-B | Difunctional compounds for degrading BTK via the ubiquitin proteasome pathway | 紐力克斯治疗公司 | 2024-07-16 | — | — | CN | disclosed |
| EP-4055019-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | Nurix Therapeutics, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, PSMB2, PSMB1 | CRBN 88/4885BRD4 294/4885MAP1LC3B 951/4885 |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, PSMB2, PSME3 | CRBN 36/4885BRD4 343/4885MAP1LC3B 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.